Minerva Advisors LLC trimmed its holdings in Kura Oncology Inc (NASDAQ:KURA) by 14.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 88,619 shares of the company’s stock after selling 14,400 shares during the period. Kura Oncology comprises about 0.8% of Minerva Advisors LLC’s portfolio, making the stock its 28th largest holding. Minerva Advisors LLC’s holdings in Kura Oncology were worth $1,551,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Voya Investment Management LLC bought a new stake in shares of Kura Oncology during the 2nd quarter valued at about $187,000. Trexquant Investment LP bought a new stake in shares of Kura Oncology during the 3rd quarter valued at about $217,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Kura Oncology during the 2nd quarter valued at about $218,000. BB&T Securities LLC bought a new stake in shares of Kura Oncology during the 2nd quarter valued at about $291,000. Finally, Credit Suisse AG grew its stake in shares of Kura Oncology by 36.7% during the 3rd quarter. Credit Suisse AG now owns 18,142 shares of the company’s stock valued at $318,000 after purchasing an additional 4,869 shares during the period. Institutional investors own 79.99% of the company’s stock.
A number of research firms have issued reports on KURA. BidaskClub downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. HC Wainwright set a $31.00 price target on Kura Oncology and gave the company a “buy” rating in a research note on Tuesday, August 7th. ValuEngine downgraded Kura Oncology from a “strong-buy” rating to a “buy” rating in a research note on Friday, October 19th. Cowen restated a “buy” rating on shares of Kura Oncology in a research note on Monday, October 22nd. Finally, Zacks Investment Research downgraded Kura Oncology from a “buy” rating to a “hold” rating in a research note on Friday, November 9th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $27.29.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, November 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.01. Equities research analysts forecast that Kura Oncology Inc will post -1.72 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Kura Oncology Inc (KURA) Shares Sold by Minerva Advisors LLC” was first published by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.wkrb13.com/2018/11/25/kura-oncology-inc-kura-shares-sold-by-minerva-advisors-llc.html.
Kura Oncology Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Further Reading: Systematic Risk and Investors
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology Inc (NASDAQ:KURA).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.